• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对接受联合化疗的转移性乳腺癌患者的总生存时间无相关影响。

No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy.

作者信息

Petru E, Schmähl D

机构信息

Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg.

出版信息

J Cancer Res Clin Oncol. 1988;114(2):183-5. doi: 10.1007/BF00417834.

DOI:10.1007/BF00417834
PMID:3350851
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12243827/
Abstract

The results of clinical studies dealing with first and second line chemotherapy of metastatic breast cancer published between 1975 and early 1986 which involved 9350 women were reviewed. Our special aim was to evaluate combination chemotherapy and its influence on overall survival in late stage breast cancer patients. No significant improvement in overall survival times was found in this selected group of patients who were treated with intense palliative chemotherapy.

摘要

对1975年至1986年初发表的涉及9350名女性的转移性乳腺癌一线和二线化疗临床研究结果进行了回顾。我们的特别目的是评估联合化疗及其对晚期乳腺癌患者总生存期的影响。在接受强化姑息化疗的这组选定患者中，未发现总生存时间有显著改善。

相似文献

1
No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy.对接受联合化疗的转移性乳腺癌患者的总生存时间无相关影响。
J Cancer Res Clin Oncol. 1988;114(2):183-5. doi: 10.1007/BF00417834.
2
Combination versus sequential single agent chemotherapy for metastatic breast cancer.转移性乳腺癌的联合化疗与序贯单药化疗对比研究
Cochrane Database Syst Rev. 2013 Dec 18;2013(12):CD008792. doi: 10.1002/14651858.CD008792.pub2.
3
Platinum-containing regimens for metastatic breast cancer.转移性乳腺癌的含铂方案。
Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Single agent versus combination chemotherapy for metastatic breast cancer.转移性乳腺癌的单药化疗与联合化疗
Cochrane Database Syst Rev. 2005 Apr 18(2):CD003372. doi: 10.1002/14651858.CD003372.pub2.
6
Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.将药物添加到转移性乳腺癌的化疗方案中。
Cochrane Database Syst Rev. 2006 Jul 19(3):CD003368. doi: 10.1002/14651858.CD003368.pub2.
7
Systemic therapy for treating locoregional recurrence in women with breast cancer.治疗乳腺癌女性局部区域复发的全身治疗
Cochrane Database Syst Rev. 2001;2001(4):CD002195. doi: 10.1002/14651858.CD002195.
8
Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.在转移性乳腺癌化疗方案中添加药物。
Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD003368. doi: 10.1002/14651858.CD003368.pub3.
9
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study.曲妥珠单抗恩美曲妥珠单抗在先前接受帕妥珠单抗治疗的转移性乳腺癌患者中的疗效和安全性的真实世界数据：土耳其肿瘤学组多中心研究。
J Chemother. 2025 Jul;37(4):334-340. doi: 10.1080/1120009X.2024.2366683. Epub 2024 Jun 21.
10
Platinum containing regimens for metastatic breast cancer.用于转移性乳腺癌的含铂方案。
Cochrane Database Syst Rev. 2004(3):CD003374. doi: 10.1002/14651858.CD003374.pub3.

引用本文的文献

1
Postmenopausal breast cancer. Drug therapy in the 1990s.绝经后乳腺癌。20世纪90年代的药物治疗。
Drugs Aging. 1993 Mar-Apr;3(2):106-21. doi: 10.2165/00002512-199303020-00002.
2
[Janus-faced character of chemotherapy: a comment on the Abel theses].[化疗的双面性：对阿贝尔论文的评论]
Klin Wochenschr. 1991 Jan 4;69(1):49-51. doi: 10.1007/BF01649059.

本文引用的文献

1
Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2'-aminophenyl)-benzamide: a new compound preferentially active in slowly growing tumors.4-氨基-N-(2'-氨基苯基)-苯甲酰胺的合成、毒性及治疗效果：一种在生长缓慢的肿瘤中具有优先活性的新化合物
Cancer Treat Rep. 1985 Dec;69(12):1415-24.
2
Estrogen-linked 2-chloroethylnitrosoureas: anticancer efficacy in MNU-induced rat mammary carcinoma, uterine activity in mice and receptor interactions.雌激素连接的2-氯乙基亚硝脲：对N-甲基-N-亚硝基脲诱导的大鼠乳腺癌的抗癌疗效、对小鼠子宫的作用及受体相互作用
Eur J Cancer Clin Oncol. 1986 Oct;22(10):1179-91. doi: 10.1016/0277-5379(86)90319-6.
3
On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations.
Wien Klin Wochenschr. 1986 Dec 5;98(23):790-7.
4
[Importance of the composition of various combination regimens in the chemotherapy of metastatic breast cancer].[不同联合方案组成在转移性乳腺癌化疗中的重要性]
Dtsch Med Wochenschr. 1987 Feb 13;112(7):270-5. doi: 10.1055/s-2008-1068044.
5
Antimetastatic effects of razoxane in a rat osteosarcoma model.
Clin Exp Metastasis. 1987 Jan-Mar;5(1):9-16. doi: 10.1007/BF00116621.
6
Alkyl phosphocholines: toxicity and anticancer properties.
Lipids. 1987 Nov;22(11):930-4. doi: 10.1007/BF02535558.
7
Does more intense palliative treatment improve overall survival in metastatic breast cancer patients?更积极的姑息治疗能否提高转移性乳腺癌患者的总生存率？
Cancer. 1986 Feb 1;57(3):567-70. doi: 10.1002/1097-0142(19860201)57:3<567::aid-cncr2820570328>3.0.co;2-y.